(BIOX) Bioceres Crop Solutions - Overview
Stock: Seed Traits, Biofertilizers, Biopesticides, Adjuvants, Inoculants
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 168% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.09 |
| Alpha | -109.02 |
| Character TTM | |
|---|---|
| Beta | 1.161 |
| Beta Downside | 0.483 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.15% |
| CAGR/Max DD | -0.67 |
Description: BIOX Bioceres Crop Solutions December 30, 2025
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) is an Argentine-based agritech firm that commercializes biological and seed-technology products across three segments: Seed & Integrated Products, Crop Protection, and Crop Nutrition. Its flagship offering, the HB4 drought-tolerant seed technology, is positioned as a climate-resilience solution for soybeans and other major crops.
In FY 2023 the company reported revenue of roughly US$140 million, driven primarily by a 22 % year-over-year increase in sales of biological inoculants and micro-granulated fertilizers-a segment that benefits from the global shift toward sustainable nutrient management. However, BIOX posted a net loss of about US$30 million, reflecting ongoing R&D intensity and the need to scale commercial operations outside its core Argentine market.
Key economic drivers for BIOX include: (1) rising global demand for low-carbon agricultural inputs, projected to grow at a CAGR of 8 % through 2030; (2) expanding adoption of drought-tolerant seed traits in South America, where climate variability is increasing yield risk; and (3) regulatory incentives in the EU and North America that favor biologically derived crop protection products over synthetic chemicals.
Assuming the company can sustain its current product rollout pace and secure additional distribution partnerships in Brazil and the United States, the upside to its valuation could be material; conversely, execution risk-particularly in scaling the HB4 program and navigating export restrictions-remains a significant uncertainty.
For a deeper quantitative comparison of BIOX against peers, the ValueRay platform offers a data-rich dashboard you may find useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -52.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.41 > 1.0 |
| NWC/Revenue: -5.21% < 20% (prev 18.41%; Δ -23.62% < -1%) |
| CFO/TA 0.08 > 3% & CFO 55.3m > Net Income -52.8m |
| Net Debt (252.2m) to EBITDA (17.0m): 14.80 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.4m) vs 12m ago 0.84% < -2% |
| Gross Margin: 39.12% > 18% (prev 0.40%; Δ 3872 % > 0.5%) |
| Asset Turnover: 40.74% > 50% (prev 53.33%; Δ -12.59% > 0%) |
| Interest Coverage Ratio: -0.07 > 6 (EBITDA TTM 17.0m / Interest Expense TTM 48.9m) |
Altman Z'' -0.61
| A: -0.02 (Total Current Assets 283.2m - Total Current Liabilities 299.7m) / Total Assets 734.9m |
| B: -0.10 (Retained Earnings -72.4m / Total Assets 734.9m) |
| C: -0.00 (EBIT TTM -3.53m / Avg Total Assets 781.1m) |
| D: -0.11 (Book Value of Equity -48.3m / Total Liabilities 455.8m) |
| Altman-Z'' Score: -0.61 = B |
Beneish M -3.15
| DSRI: 1.14 (Receivables 170.7m/207.4m, Revenue 318.2m/441.2m) |
| GMI: 1.03 (GM 39.12% / 40.21%) |
| AQI: 1.14 (AQ_t 0.49 / AQ_t-1 0.43) |
| SGI: 0.72 (Revenue 318.2m / 441.2m) |
| TATA: -0.15 (NI -52.8m - CFO 55.3m) / TA 734.9m) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of BIOX shares?
Over the past week, the price has changed by -32.55%, over one month by -63.07%, over three months by -65.96% and over the past year by -89.87%.
Is BIOX a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BIOX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2 | 250.9% |
| Analysts Target Price | 2 | 250.9% |
| ValueRay Target Price | 0.4 | -36.8% |
BIOX Fundamental Data Overview February 04, 2026
P/S = 0.1724
P/B = 0.24
P/EG = 1.9521
Revenue TTM = 318.2m USD
EBIT TTM = -3.53m USD
EBITDA TTM = 17.0m USD
Long Term Debt = 53.8m USD (from longTermDebt, last quarter)
Short Term Debt = 191.9m USD (from shortTermDebt, last quarter)
Debt = 267.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 252.2m USD (from netDebt column, last quarter)
Enterprise Value = 306.0m USD (54.9m + Debt 267.7m - CCE 16.6m)
Interest Coverage Ratio = -0.07 (Ebit TTM -3.53m / Interest Expense TTM 48.9m)
EV/FCF = 8.37x (Enterprise Value 306.0m / FCF TTM 36.5m)
FCF Yield = 11.94% (FCF TTM 36.5m / Enterprise Value 306.0m)
FCF Margin = 11.48% (FCF TTM 36.5m / Revenue TTM 318.2m)
Net Margin = -16.60% (Net Income TTM -52.8m / Revenue TTM 318.2m)
Gross Margin = 39.12% ((Revenue TTM 318.2m - Cost of Revenue TTM 193.7m) / Revenue TTM)
Gross Margin QoQ = 40.95% (prev 32.53%)
Tobins Q-Ratio = 0.42 (Enterprise Value 306.0m / Total Assets 734.9m)
Interest Expense / Debt = 3.40% (Interest Expense 9.12m / Debt 267.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.79m (EBIT -3.53m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.94 (Total Current Assets 283.2m / Total Current Liabilities 299.7m)
Debt / Equity = 1.07 (Debt 267.7m / totalStockholderEquity, last quarter 249.4m)
Debt / EBITDA = 14.80 (Net Debt 252.2m / EBITDA 17.0m)
Debt / FCF = 6.90 (Net Debt 252.2m / FCF TTM 36.5m)
Total Stockholder Equity = 282.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.76% (Net Income -52.8m / Total Assets 734.9m)
RoE = -18.69% (Net Income TTM -52.8m / Total Stockholder Equity 282.7m)
RoCE = -1.05% (EBIT -3.53m / Capital Employed (Equity 282.7m + L.T.Debt 53.8m))
RoIC = -0.51% (negative operating profit) (NOPAT -2.79m / Invested Capital 542.1m)
WACC = 3.97% (E(54.9m)/V(322.6m) * Re(10.19%) + D(267.7m)/V(322.6m) * Rd(3.40%) * (1-Tc(0.21)))
Discount Rate = 10.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.35%
[DCF Debug] Terminal Value 81.36% ; FCFF base≈27.1m ; Y1≈18.4m ; Y5≈8.96m
Fair Price DCF = 0.49 (EV 283.4m - Net Debt 252.2m = Equity 31.2m / Shares 63.5m; r=5.90% [WACC]; 5y FCF grow -37.58% → 2.90% )
EPS Correlation: -23.96 | EPS CAGR: 7.07% | SUE: -0.29 | # QB: 0
Revenue Correlation: -24.76 | Revenue CAGR: -4.58% | SUE: -0.75 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=+0.035 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-06-30): EPS=-0.16 | Chg30d=+0.130 | Revisions Net=-2 | Growth EPS=+80.5% | Growth Revenue=-7.9%
EPS next Year (2027-06-30): EPS=0.05 | Chg30d=+0.110 | Revisions Net=+1 | Growth EPS=+117.1% | Growth Revenue=+18.1%